RB1 and posterior cortical atrophy: A small percentage (1–2%) of newly diagnosed PCa may present as de novo AR− neuroendocrine PCa (NEPC), which is most frequently associated with mutations or loss of tumor suppressor genes RB1 and/or TP53.